Our Network

Omico is a nationwide network of research and treatment centres that facilitate, support and promote genomic cancer medicine. Central to this is the use of molecular screening for the prevention and treatment of cancer.

New South Wales

Garvan Institute of Medical Research (MoST, RiSC and SMOC+ screening) (ASPiRATION – **open** for screening)

NHMRC Clinical Trials Centre (University of Sydney)

The Kinghorn Cancer Centre (St Vincent’s Hospital, Darlinghurst) (MoST, RiSC and SMOC+)

Chris O’brien Lifehouse (Camperdown) (MoST and RiSC) (ASPiRATION date to be advised – 2021)

St George Hospital (Kogarah) (MoST) (ASPiRATION date to be advised 2021)

Royal North Shore Hospital (North Sydney) (ASPiRATION – **open** for screening)

Westmead Hospital (Westmead) (ASPiRATION date to be advised 2021)

Prince of Wales Hospital (Randwick) (MoST) (opening soon)

Victoria

Peter MacCallum Cancer Centre (MoST, RiSC and SMOC+) (ASPiRATION – **open** for screening)

Monash Partners Comprehensive Cancer Consortium (MoST screening)

Austin Health (MoST opening soon) (ASPiRATION date to be advised 2021)

St Vincent’s Hospital, Fitzroy (ASPiRATION date to be advised 2021)

Tasmania

Royal Hobart Hospital (MoST) (ASPiRATION – **open** for screening)

Australian Capital Territory

Canberra Hospital (MoST) (ASPiRATION date to be advised 2021)

Queensland

Princess Alexandra Hospital (MoST) (ASPiRATION – opening soon)

Royal Brisbane and Women’s Hospital (MoST-LLy) (opening soon)

Prince Charles Hospital (ASPiRATION date to be advised 2021)

Pathology Queensland

South Australia

Royal Adelaide Hospital (MoST and SMOC+) (MoST-LLy – opening soon) (ASPiRATION – **open** for screening)

South Australia Pathology

Northern Territory

Royal Darwin Hospital (MoST) (ASPiRATION date to be advised 2021)

Western Australia

Linear Clinical Research Limited (MoST) (ASPiRATION – **open** for screening)

Sir Charles Gairdner Hospital (MoST)

Pathwest

Our Members